Beranda › Leukemia Mieloid Fase Kronis › Texas
Uji klinis Leukemia Mieloid Fase Kronis di Texas
6 studi untuk Leukemia Mieloid Fase Kronis mencari peserta di lokasi di Texas.
Kota di Texas
Teks studi resmi (Bahasa Inggris)
Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib
- M D Anderson Cancer Center, Houston
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT01746836Study of Olverembatinib (HQP1351) in Patients With CML-CP
- Ascentage Investigative Site #1051, Amarillo
- Ascentage Investigative Site #1036, Austin
- Ascentage Investigative Site #1501, Houston
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT06423911Personalized NK Cell Therapy in CBT
- M D Anderson Cancer Center, Houston
Menerima pesertaFase 2
Usia 15 hingga 80 · Semua jenis kelamin · Diperbarui 30 Jul 2026 · NCT02727803A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy
- Baylor Scott and White Research, Temple
Menerima pesertaStudi observasional
Usia 18 hingga 100 · Semua jenis kelamin · Diperbarui 20 Jul 2026 · NCT07091019A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
- The University of Texas MD Anderson Cancer Center, Houston
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Apr 2026 · NCT05304377A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)
- The University of Texas M.D. Anderson Cancer Center, Houston
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 12 Jan 2026 · NCT06163430Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.